報價延遲最少15分鐘:2026/04/25 08:48 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
46.78 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
3.19/4.48
|
|
企業價值
129.59B
|
| 資產負債 |
|
每股賬面淨值
34.99
|
| 現金流量 |
|
現金流量率
0.11
|
| 損益表 |
|
收益
32.00B
|
|
每股收益
20.19
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profitsfor this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China. |
